Imperva Inc. (IMPV) Rating Lowered to Neutral at Nomura
Imperva Inc. (NYSE:IMPV) was downgraded by Nomura from a “buy” rating to a “neutral” rating in a report released on Monday. They presently have a $50.00 price target on the stock. Nomura’s target price points to a potential downside of 5.32% from the company’s current price.
Other equities research analysts have also issued reports about the company. Wunderlich started coverage on Imperva in a report on Tuesday, September 13th. They set a “hold” rating and a $50.00 price target for the company. Pacific Crest lowered Imperva from an “overweight” rating to a “sector weight” rating and reduced their price target for the company from $47.00 to $30.00 in a report on Tuesday, August 30th. BTIG Research reiterated a “buy” rating and set a $55.00 price target on shares of Imperva in a report on Tuesday, June 21st. Oppenheimer Holdings Inc. reiterated an “outperform” rating and set a $60.00 price target on shares of Imperva in a report on Friday, September 23rd. Finally, Morgan Stanley reiterated a “sell” rating on shares of Imperva in a report on Thursday, June 30th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and fourteen have given a buy rating to the company’s stock. Imperva currently has a consensus rating of “Buy” and a consensus target price of $53.33.
Shares of Imperva (NYSE:IMPV) opened at 52.81 on Monday. The firm’s market cap is $1.72 billion. Imperva has a 52-week low of $31.11 and a 52-week high of $77.99. The stock’s 50 day moving average is $46.37 and its 200-day moving average is $44.33.
Imperva (NYSE:IMPV) last announced its quarterly earnings data on Thursday, August 4th. The company reported ($0.23) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.04) by $0.19. Imperva had a negative return on equity of 25.68% and a negative net margin of 23.75%. The business had revenue of $57.87 million for the quarter, compared to analyst estimates of $66.06 million. During the same quarter in the previous year, the business posted ($0.08) earnings per share. The company’s revenue was up 8.2% compared to the same quarter last year. Equities analysts anticipate that Imperva will post ($0.80) earnings per share for the current fiscal year.
In related news, insider Amichai Shulman sold 3,085 shares of the business’s stock in a transaction on Wednesday, July 27th. The stock was sold at an average price of $46.28, for a total value of $142,773.80. Following the sale, the insider now owns 93,380 shares of the company’s stock, valued at approximately $4,321,626.40. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Mark E. Kraynak sold 2,967 shares of the business’s stock in a transaction on Tuesday, July 26th. The shares were sold at an average price of $46.15, for a total value of $136,927.05. Following the completion of the sale, the senior vice president now directly owns 2,968 shares in the company, valued at approximately $136,973.20. The disclosure for this sale can be found here. 2.20% of the stock is owned by corporate insiders.
Hedge funds have recently made changes to their positions in the stock. Credit Suisse AG raised its stake in shares of Imperva by 865.9% in the second quarter. Credit Suisse AG now owns 1,431,447 shares of the company’s stock valued at $61,568,000 after buying an additional 1,283,243 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Imperva by 46.8% in the first quarter. JPMorgan Chase & Co. now owns 1,479,012 shares of the company’s stock valued at $74,688,000 after buying an additional 471,250 shares in the last quarter. Pictet Asset Management Ltd. raised its stake in shares of Imperva by 50.6% in the second quarter. Pictet Asset Management Ltd. now owns 804,552 shares of the company’s stock valued at $30,718,000 after buying an additional 270,312 shares in the last quarter. FIL Ltd bought a new stake in shares of Imperva during the second quarter valued at approximately $10,170,000. Finally, Jet Capital Investors L P bought a new stake in shares of Imperva during the second quarter valued at approximately $9,670,000. 93.26% of the stock is currently owned by institutional investors and hedge funds.
Imperva Company Profile
Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company operates in the segment of development, marketing, sales, service and support of cyber-security solutions that protect business critical data and applications whether in the cloud or on premises.
Receive News & Stock Ratings for Imperva Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva Inc. and related stocks with our FREE daily email newsletter.